Most cancer drugs don’t actually kill cancer — they just slow it down.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, reveals why many FDA-approved cancer treatments are cytostatic, meaning they only halt tumor growth — not destroy it. The future, he says, is in cytotoxic precision oncology: treatments designed to actually kill cancer cells while sparing healthy ones.

Dr. Prato breaks down the crucial difference between managing and eliminating cancer, and explains why the immune system must be engaged for durable remissions. Using deep mapping tools like DNA, RNA, spatial biology, and immune profiling, Envita customizes therapies that combine precision targeting with immune activation — shifting the goal from “control” to “cure-driven remission.”

🎯 What You’ll Learn in This Episode:

• The real difference between cytostatic and cytotoxic drugs
• Why most new cancer drugs are designed to manage, not eliminate, disease
• How the immune system provides true cytotoxic killing power
• Why immunotherapy (PD-1s, NK cells) needs customization
• How deep mapping (DNA, RNA, spatial biology) reveals better treatment targets
• How Envita achieved up to 35x improved outcomes in late-stage patients*
  
  

📊 In published outcomes, precision oncology achieved up to 35x better responses and 43x improved quality of life by focusing on cytotoxic, immune-centered treatment algorithms.
*(See Outcomes Disclaimer Below)

“Managing cancer isn’t enough — it’s time to design care that actually kills it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Patients don’t die of cancer alone — they die from waiting.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes how the cancer system’s slow approvals, outdated guidelines, and insurance roadblocks cost patients precious time. Care delayed is care denied — and that’s why Dr. Prato and his team built a precision ecosystem to help patients access advanced, individualized care now.

Discover how N of one precision oncology eliminates delays by combining next-generation DNA/RNA sequencing, immune profiling, spatial biology, and molecular heat mapping to design treatments unique to every patient.

🎯 What You’ll Learn in This Episode:

• Why prior authorizations and step therapies delay lifesaving care
• How “population health” oncology ignores your personal biology
• The truth about drug pipelines designed to manage — not cure — cancer
• How precision mapping (DNA, RNA, immune, spatial) speeds effective treatment
• Why waiting on outdated clinical trial models costs lives

How patients see 35x better responses and 43x better quality of life using targeted, personalized care*

📊 In Envita’s published data, late-stage cancer patients achieved dramatically improved outcomes through precision-matched treatments — without the long delays of traditional oncology.*
*(See Outcomes Disclaimer Below)

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“Care delayed is care denied. Precision care saves time — and lives.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

What if the best prostate cancer treatment doesn’t cut, burn, or destroy your vitality — yet still teaches your immune system to find and fight cancer throughout the body?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology and interventional radiology are redefining prostate cancer care. Instead of relying on radical surgery or radiation, Envita uses deep DNA/RNA sequencing, immune profiling, and 3D cone-beam imaging to guide minimally invasive, immune-centered procedures.

Dr. Prato discusses the risks of standard prostate surgery — including incontinence, erectile dysfunction, and long-term recurrence — and how precision targeting eliminates guesswork by treating the tumor directly and stimulating the immune system for long-term remission.

🎯 What You’ll Learn in This Episode:

• Why up to 50% of men experience PSA recurrence after prostate surgery

• How interventional oncology delivers treatment directly to the tumor site

• Why immune-based, precision care improves long-term outcomes

• The difference between radical surgery and image-guided microcatheter treatment

• How DNA, RNA, and spatial biology testing reveal cancer’s weak points

• Why deep mapping prevents recurrence and protects quality of life

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“The future of prostate cancer care is precise, personalized, and immune-centered.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493